Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity

Oncogene

Volumn 32, Issue 3, 2013, Pages 397-402

  Van Der Weyden, L ^a   Rust, A G ^a   McIntyre, R E ^a   Robles Espinoza, C D ^a   Del Castillo Velasco Herrera, M ^a   Strogantsev, R ^b   Ferguson Smith, A C ^b   McCarthy, S ^a   Keane, T M ^a   Arends, M J ^b   Adams, D J ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

heterozygosity; Jdp2; lymphoma; mice; p53; transposon

Indexed keywords

JUN DIMERIZATION PROTEIN 2; TRANSCRIPTION FACTOR; TRANSPOSASE; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE INSERTION; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENOTYPE; HETEROZYGOTE; HUMAN; LEUKEMOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SOMATIC MUTATION; TRANSCRIPTION REGULATION; TRANSPOSON; TRP53 GENE;

MUS;

EID: 84872616146     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.56     Document Type: Article

References (42)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
2. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998; 12: 2973-2983.
3. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.
4. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Path 2011; 223: 116-126.
5. Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2010; 2: a001016.
6. Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 2703-2708.
7. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998; 17: 4657-4667.
8. Venkatachalam S, Tyner SD, Pickering CR, Boley S, Recio L, French JE et al. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/-mouse model in carcinogenicity testing. Toxicol Pathol 2001; 29: 147-154.
9. Donehower LA. Using mice to examine p53 functions in cancer, aging, and longevity. Cold Spring Harb Perspect Biol 2009; 1: a001081.
10. Donehower LA, Lozano G. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 2009; 9: 831-841.
11. Li FP, Fraumeni Jr JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71: 747-752.
12. Malkin D, Li FP, Strong LC, Fraumeni Jr JF, Nelson CE, Kim DH et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
13. Sedlacek Z, Kodet R, Kriz V, Seemanova E, Vodvarka P, Wilgenbus P et al. Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours. Br J Cancer 1998; 77: 1034-1039.
14. Maiguel DA, Jones L, Chakravarty D, Yang C, Carrier F. Nucleophosmin sets a threshold for p53 response to UV radiation. Mol Cell Biol 2004; 24: 3703-3711.
15. Zheng B, Vogel H, Donehower LA, Bradley A. Visual genotyping of a coat color tagged p53 mutant mouse line. Cancer Biol Ther 2002; 1: 433-435.
16. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 2005; 436: 272-276.
17. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 2005; 436: 221-226.
18. Uren AG, Mikkers H, Kool J, van der Weyden L, Lund AH, Wilson CH et al. A highthroughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc 2009; 4: 789-798.
19. de Ridder J, Uren A, Kool J, Reinders M, Wessels L. Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol 2006; 2: e166.
20. March HN, Rust AG, Wright NA, ten Hoeve J, de Ridder J, Eldridge M et al. Insertional mutagenesis reveals multiple networks of co-operating genes driving intestinal mutagenesis. Nat Genet 2011; 43: 1202-1209.
21. Demarest RM, Ratti F, Capobianco AJ. It's T-ALL about Notch. Oncogene 2008; 27: 5082-5091.
22. Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN et al. Wholebody sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res 2009; 69: 8429-8437.
23. Dube N, Kooistra MR, Pannekoek WJ, Vliem MJ, Oorschot V, Klumperman J et al. The RapGEF PDZ-GEF2 is required for maturation of cell-cell junctions. Cell Signal 2008; 20: 1608-1615.
24. Severson EA, Lee WY, Capaldo CT, Nusrat A, Parkos CA. Junctional adhesion molecule A interacts with Afadin and PDZ-GEF2 to activate Rap1A, regulate beta1 integrin levels, and enhance cell migration. Mol Biol Cell 2009; 20: 1916-1925.
25. Iwasaki M, Tanaka R, Hishiya A, Homma S, Reed JC, Takayama S. BAG3 directly associates with guanine nucleotide exchange factor of Rap1, PDZGEF2, and regulates cell adhesion. Biochem Biophys Res Commun 2010; 400: 413-418.
26. Giguè re A, Hebert J. Microhomologies and topoisomerase II consensus sequences identified near the breakpoint junctions of the recurrent t(7;21)(p22;q22) translocation in acute myeloid leukemia. Genes Chromosomes Cancer 2011; 50: 228-238.
27. Gutierrez A, Grebliunaite R, Feng H, Kozakewich E, Zhu S, Guo F et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med 2011; 208: 1595-1603.
28. Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B et al. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci USA 2010; 107: 5106-5111.
29. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
30. Uren AG, Kool J, Matentzoglu K, de Ridder J, Mattison J, van Uitert M et al. Largescale mutagenesis in p19(ARF)-and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 2008; 133: 727-741.
31. Aronheim A, Zandi E, Hennemann H, Elledge SJ, Karin M. Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. Mol Cell Biol 1997; 17: 3094-3102.
32. Bitton-Worms K, Pikarsky E, Aronheim A. The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. Mol Cancer 2010; 9: 54.
33. Stewart M, Mackay N, Hanlon L, Blyth K, Scobie L, Cameron E et al. Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas. Cancer Res 2007; 67: 5126-5133.
34. Rasmussen MH, Wang B, Wabl M, Nielsen AL, Pedersen FS. Activation of alternative Jdp2 promoters and functional protein isoforms in T-cell lymphomas by retroviral insertion mutagenesis. Nuc Acids Res 2009; 37: 4657-4671.
35. Yuanhong X, Feng X, Qingchang L, Jianpeng F, Zhe L, Kejian G. Downregulation of AP-1 repressor JDP2 is associated with tumor metastasis and poor prognosis in patients with pancreatic carcinoma. Int J Biol Markers 2010; 25: 136-140.
36. Nakade K, Pan J, Yamasaki T, Murata T, Wasylyk B, Yokoyama KK. JDP2 (Jun Dimerization Protein 2)-deficient mouse embryonic fibroblasts are resistant to replicative senescence. J Biol Chem 2009; 284: 10808-10817.
37. Wang SW, Lee JK, Ku CC, Chiou SS, Ho MF, Wu DC et al. Jun dimerization protein 2 in oxygen restriction; control of senescence. Curr Pharm Des 2011; 17: 2278-2289.
38. Pan J, Nakade K, Huang YC, Zhu ZW, Masuzaki S, Hasegawa H et al. Suppression of cell-cycle progression by Jun dimerization protein-2 (JDP2) involves downregulation of cyclin-A2. Oncogene 2010; 29: 6245-6256.
39. Ji H, Ehrlich LI, Seita J, Murakami P, Doi A, Lindau P et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010; 467: 338-342.
40. Uren AG, Kool J, Berns A, van Lohuizen M. Retroviral insertional mutagenesis: past, present and future. Oncogene 2005; 24: 7656-7672.
41. Piu F, Aronheim A, Katz S, Karin M. AP-1 repressor protein JDP-2: inhibition of UV-mediated apoptosis through p53 down-regulation. Mol Cell Biol 2001; 21: 3012-3024.
42. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.